Adverse drug reactions: Part II

Southern Medical Journal

Volumn 103, Issue 11, 2010, Pages 1138-1145

  Wooten, James M ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

Author keywords

adverse drug reactions; adverse reactions; drugs; pharmacology

Indexed keywords

ALCOHOL; CISAPRIDE; CYTOCHROME P450; DIETHYLSTILBESTROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENCAINIDE; ISOTRETINOIN; LEVOTHYROXINE; LORAZEPAM; METHOTREXATE; PREDNISONE; RETINOIC ACID; ROFECOXIB; TEGASEROD; TERATOGENIC AGENT; TROVAFLOXACIN; WARFARIN;

ADVERSE DRUG REACTION; AGED; ANGIONEUROTIC EDEMA; BREAST FEEDING; CHILD; CLINICAL ASSESSMENT; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG INDICATION; DRUG INFORMATION; DRUG MARKETING; DRUG PACKAGING; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ETHNICITY; GERIATRIC PATIENT; GLOMERULUS FILTRATION RATE; HEALTH CARE PERSONNEL; HOSPITAL PHARMACY; HUMAN; KIDNEY CLEARANCE; LIVER METABOLISM; MEDICAL INFORMATION SYSTEM; PHARMACODYNAMICS; PHARMACOGENETICS; PHARMACY; POSTMARKETING SURVEILLANCE; PREGNANT WOMAN; PRESCRIPTION; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; TERATOGENICITY;

ADOLESCENT; AGED; CHILD; CHILD, PRESCHOOL; DRUG MONITORING; DRUG TOXICITY; FEMALE; GERIATRIC ASSESSMENT; HUMANS; INFANT; INFANT, NEWBORN; PREGNANCY; PRENATAL CARE; PRODUCT SURVEILLANCE, POSTMARKETING; RISK ASSESSMENT; RISK FACTORS;

EID: 78549255522     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e3181f5ecb5     Document Type: Review

References (43)

1. Wooten J. Adverse drug reactions: part I. South Med J 2010;103:1025-1030.
2. Gray CL, Gardner C. Adverse drug events in the elderly: an ongoing problem. J Manag Care Pharm 2009;15:568-571.
3. Wright RM, Warpula RW. Geriatric pharmacology: safer prescribing for the elderly patient. J Am Pod Med Assoc 2004;94:90-97.
4. Riedl MA, Cassillas AM. Adverse drug reactions: types and treatment options. Am Fam Physician 2003;68:1781-1790.
5. Oberg KC. Adverse drug reactions. Am J Pharm Ed 1999;63:199-204.
6. Beyth RJ, Short RI. Principles of drug therapy in older patients: rational drug prescribing. Clin Geriatr Med 2002;18:577-592.
7. Routledge PA, O'Mahony MS, Woodhouse KW. Adverse drug reactions in elderly patients. Br J Clin Pharmacol 2003;57:121-126.
8. Okie S. Safety in numbers-monitoring risk in approved drugs. N Engl J Med 2005;352:1173-1176.
9. Blanda MP. Pharmacologic issues in geriatric emergency medicine. Emerg Med Clin North Am 2006;24:449-465.
10. Fick DM, Cooper JW, Wade WE, et al. Updating the beers criteria for potentially inappropriate medication use in older adults. Arch Intern Med 2003;163:2716-2724.
11. American Academy of Pediatrics, 2007. Available at: http://www.aap. org/advocacy/washing/Therapeutics/docs/coalitionbpcaprea.pdf. Accessed on January 29, 2010.
12. Verhamme K, Bonifazi F, Ceci A, et al. Adverse drug reactions reporting in children. Pharm Policy Law 2009;11:89-99.
13. Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. Ann Intern Med 2004;140:795-801.
14. Fattahi F, Pourpak Z, Moin M, et al. Adverse drug reactions in hospitalized children in a department of infectious diseases. J Clin Pharmacol 2005;45:1313-1318.
15. Peterson RG, Turner C. The physician's role and responsibility in reporting adverse drug events in children. Paediatr Child Health 2003;8: 213-214.
16. Pillans PI. Clinical perspectives in drug safety and adverse drug reactions. Expert Rev Clin Pharmacol 2008;1:695-705.
17. Larimore WL, Petrie KA. Drug use during pregnancy and lactation. Prim Care 2000;27:35-53.
18. Rayburn WF, Amanze AC. Prescribing medications safely during pregnancy. Med Clin N Am 2008;92:1227-1237.
19. Carson MP, Ehrenthal D. Medical issues from preconception through delivery: a roadmap for the internist. Med Clin N Am 2008;92:1193-1225.
20. Eglash A, Montgomery A, Wood J. Breastfeeding. Dis Mon 2008;54: 343-411.
21. Ritter JM. Communicating about potential drug harms: safety implications for patients. Br J Clin Pharmacol 2009;68:147-148.
22. US Food and Drug Administration. Available at: http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071639.pdf. Accessed March 3, 2010.
23. Gibbs CR, Lip GY, Beevers DG. Angioedema due to ACE inhibitors: increased risk in patients of African origin. Br J Clin Pharmacol 1999; 48:861-865.
24. Tseng DS, Kwong J, Rezvani F, et al. Angiotensin-converting enzyme-related cough among Chinese-Americans. Am J Med 2010;123:183.e11-183.e15.
25. Hart JA. Do adverse drug reactions to cardiovascular medicines differ among ethnic groups? A viewpoint. BMJ 2006;332:1177-1181.
26. Brown SD Jr, Landry FJ. Recognizing, reporting, and reducing adverse drug reactions. South Med J 2001;94:370-373.
27. Alfirevic A, Pirmohamed M. Adverse drug reactions and pharmacog-enomics: recent advances. Per Med 2008;5:11-23.
28. Ingelman-Sundberg M. Pharmacogenomic biomarkers for prediction of severe adverse drug reactions. N Engl J Med 2008;358:637-639.
29. Avigan M. Pharmacogenomic biomarkers of susceptibility to adverse drug reactions: just around the corner or pie in the sky? Per Med 2009; 6:67-78.
30. Corrigan OP. A risky business: the detection of adverse drug reactions in clinical trials and post-marketing exercises. Soc Sci Med 2002;55: 497-507.
31. United States Food and Drug Administration MedWatch Program. Available at: http://www.fda.gov/drugs/guidancecomplianceregulatory information/ surveillance/adversedrugeffects/default.htm. Accessed March 3, 2010.
32. Brewer T, Colditz GA. Postmarketing surveillance and adverse drug reactions: current perspectives and future needs. JAMA 1999;281:824-829.
33. Roden DM. An underrecognized challenge in evaluating postmarketing drug safety. Circulation 2005;111:246-248.
34. Worst Pills. Available at: http://www.worstpills.org/index.cfm. Accessed March 3, 2010.
35. Wright JM. Why don't we initiate more large simple randomized controlled trials? CMAJ 2003;169:1170-1171.
36. US Food and Drug Administration. Drugs. Available at: http://www.fda. gov/Drugs/default.htm. Accessed March 3, 2010
37. Adverse event reporting\Why and How? American Pharmacists Association 2008. Available at: https://www.aphanet.org/AM/Template.cfm? Section=Home2&CONTENTID=15795&TEMPLATE=/CM/Content Display.cfm. Accessed March 3, 2010.
38. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30: 239-245.
39. US Department of Health and Human Services. Reducing and preventing adverse drug events to decrease hospital costs. Available at: http://www.ahrq.gov/qual/aderia/aderia.htm#ADEsPrevented. Accessed March 3, 2010.
40. Jha AK, Laguette J, Seger A, et al. Can surveillance systems identify and avert adverse drug events? A prospective evaluation of a commercial application. J Am Med Inform Assoc 2008;15:647-653.
41. Brassey J. Electronic resources reviews. J Med Libr Assoc 2007;95:215-225.
42. Breckenridge A, Woods K, Raine J. Monitoring the safety of licensed medicines. Nat Rev Drug Discov 2005;4:541-537.
43. Gandhi TK, Weingart SN, Borus J, et al. Adverse drug events in ambulatory care. NEngl JMed 2003;348:1556-64